Navigation Links
Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
Date:1/14/2008

America and Europe.

The company's second Phase 3 trial, VITAL-2, is a multi-center, randomized, controlled Phase 3 clinical trial designed to evaluate the safety and efficacy of GVAX immunotherapy for prostate cancer used in combination with Taxotere chemotherapy compared to the use of Taxotere chemotherapy and prednisone in HRPC patients with metastatic disease who are symptomatic with cancer-related pain. The primary endpoint of the trial is also an improvement in survival. VITAL-2 was initiated in June 2005 and is currently enrolling patients at approximately 90 sites in North America and Europe. The company expects to complete enrollment of approximately 600 patients in the first half of 2009 and if this is achieved, to have a sufficient number of events for a pre-planned interim analysis at that time.

The U.S. Food and Drug Administration (FDA) granted Cell Genesys Special Protocol Assessments (SPAs) for both VITAL-1 and VITAL-2. The SPA is a process that allows for official FDA evaluation of a Phase 3 clinical trial and provides trial sponsors with a binding written agreement that the design and analysis of the study are adequate to support a license application submission if that study is performed according to the SPA. Cell Genesys completed the modifications requested by FDA during the review process.

About GVAX Cancer Immunotherapies

GVAX cancer immunotherapies are non patient-specific investigational therapeutics comprised of whole tumor cells that have been modified to secrete GM-CSF (granulocyte-macrophage colony stimulating factor), an immune stimulatory hormone, and then irradiated for safety. GVAX is designed to be administered through intradermal injections on an outpatient basis. To date, over 600 patients have been treated with GVAX cancer immunotherapies in Phase 1 and Phase 2 clinical trials for multiple indications, including prostate cancer, pancreatic cancer, and leukemia. The company is currently manufacturing GV
'/>"/>

SOURCE Cell Genesys, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
10. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
11. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... 14 Gibraltar Associates, a leading ... and domestic communications and issues management, today ... with PositiveID Corporation (Nasdaq: PSID ) ... agency of record. Gibraltar Associates will conduct ... advise the Company on its public relations ...
(Date:12/14/2009)... -- VION PHARMACEUTICALS, INC. (OTC Bulletin ... a complete response letter from the U.S. Food ... Drug Application ("NDA") for Onrigin(TM) (laromustine) injection submitted ... the FDA cannot approve the Company,s NDA in ... remaining issues. ,, Alan Kessman, Chief Executive Officer, ...
(Date:12/14/2009)... HELSINKI, Dec. 14 Cancer patients in ... with the introduction of RapidArc® radiotherapy technology from ... at the only private radiotherapy clinic in the ... are using this fast and precise form of ... and cancers of the abdomen and prostate. ,, ...
Breaking Medicine Technology:Gibraltar Associates Named Agency of Record for Health Information and Diagnostic Provider PositiveID Corporation 2Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration 2Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration 3Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 2Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 3Study Finds Racial Inequalities Cost U S Health System Over 2450 Billion a Year 57473 1Study Finds Racial Inequalities Cost U S Health System Over 2450 Billion a Year 57473 2Study Finds Racial Inequalities Cost U S Health System Over 2450 Billion a Year 57473 3Study Finds Racial Inequalities Cost U S Health System Over 2450 Billion a Year 57473 4Cowen Healthcare Royalty Partners Establishes Strategic Advisory Board 14117 1Cowen Healthcare Royalty Partners Establishes Strategic Advisory Board 14117 2Cowen Healthcare Royalty Partners Establishes Strategic Advisory Board 14117 3Cowen Healthcare Royalty Partners Establishes Strategic Advisory Board 14117 4Intarcia Therapeutics Inc Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes 14115 1Intarcia Therapeutics Inc Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes 14115 2Intarcia Therapeutics Inc Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes 14115 3
(Date:12/15/2009)... January 1, 2010 Oregon will require that certain businesses with ... automated external defibrillator (AED) readily available. Fire and rescue personnel ... AED is a good investment. , ... ... 1, 2010 Oregon will require that certain businesses with large ...
(Date:12/15/2009)... the Dec. 15 issue of the Journal of ... obese increases the risk for developing obstructive sleep apnea ... , Results indicate that the risk of OSA ... increased 3.5 fold with each standard-deviation increase in body ... did not significantly increase with increasing BMI among younger ...
(Date:12/14/2009)... BROOK, Ill., Dec. 15 In today,s ... larger role than ever. Now the University HealthSystem ... resources, Value Analysis: Achieving Cost Efficiencies in ... in these complex environments. These new materials, developed ... the field, provide a practical guide to planning, ...
(Date:12/14/2009)... ABBOTT PARK, Ill. and HOLLYWOOD, Fla., Dec. ... ABT ) announced today a definitive agreement ... LIMS ), a leading provider of laboratory ... in cash. ,, The acquisition strengthens ... market, providing advanced web-based applications to help ...
(Date:12/14/2009)... Incorporated announced today that it has priced $400 ... a coupon of 6.9%. The notes will be ... 6.984%. The company anticipates using the proceeds from ... purposes. ,, Commenting on the pricing of the ... Officer Kriss Cloninger III commented: "This debt issuance ...
Breaking Medicine News(10 mins):Health News:QuickMedical Responds to Oregon Bill Requiring Businesses to Carry Defibrillators 2Health News:QuickMedical Responds to Oregon Bill Requiring Businesses to Carry Defibrillators 3Health News:Obesity increases the risk for obstructive sleep apnea in adolescents, but not in younger children 2Health News:University HealthSystem Consortium Offers Value Analysis Professionals Insightful New Resources 2Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 2Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 3Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 4Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 2Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 3Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 4
... profound effect on the psychological behavior in adulthood. It has ... full term but weighing below 5.5 lbs are at 50% ... same after taking into consideration various factors likes father’s social ... has been unclear whether the effect of low birth weight ...
... Vaccines for prophylaxis are well known. Famous vaccines include ... etc.; Therapeutic vaccines to cure a condition are more ... include the ones against HIV and hepatitis. The therapeutic ... combat an infectious agent, such as a virus. Now ...
... of autistic children have led to a fear in the ... autistic epidemic. However a recent report, which was published in ... this is not true. The report points out to certain ... ,The study had pointed out that recent changes in ...
... in the International Journal of Epidemiology has implicated maternal ... arthritis and other inflammatory polyarthropathies(RA&IP )during the first ... chronic inflammatory disorder that leads to the destruction of ... of the joints. Several studies have shown that maternal ...
... used for prevention of pregnancy for decades and more recently ... that wearing a condom during intercourse may not give good ... and syphilis. ,There has been a rise recently in ... the news may come as a surprise to many. Current ...
... at risk of having a pre-term baby may perhaps will ... // that pomegranate juice can prevent brain injury the fetus ... flow in case of a pre-term delivery., ,Pomegranate juice ... potential property of neuroprotection and anti-aging effects. ,Researchers ...
Other Medicine News:Health News:Is low birth weight related to psychological distress in adulthood? 2Health News:Understanding Chronic Infections May Help in Developing Therapeutic Vaccines 2Health News:Condoms May not be safe Enough 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: